Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06894771 · ClinicalTrials.gov registry record · Phase 1
A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT06894771 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 5 participants.
The verdict
NCT06894771, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The goal of this study is to learn about the safety of different doses of MK-4700 and if people tolerate them. The study will also measure what happens in a person's body over time when MK-4700 is given alone or with pembrolizumab (MK-3475) in order to find a dose that is safe, tolerated, and may work to treat certain types of cancer.
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL MK-4700
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2025-04-23 |
| Est. Completion | 2025-12-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06894771
The ClinicalTrials.gov registry entry for NCT06894771 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06894771 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06894771 about?
NCT06894771 is a clinical study titled "A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)". The goal of this study is to learn about the safety of different doses of MK-4700 and if people tolerate them. The study will also measure what happens in a person's body over time when MK-4700 is given alone or with pembrolizumab (MK-3475) in order to find a dose that is safe, tolerated, and may wo...
What is the current status of trial NCT06894771?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2025-04-23. Estimated completion is 2025-12-08.
What interventions are being tested in trial NCT06894771?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), MK-4700 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06894771?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.